What was Ironwood's revenue in Q1 2026?

Ironwood's revenue was $123.4 million, beating estimates of $120 million.

Why did Ironwood's stock fall despite beating estimates?

The stock fell 2.5% after the announcement, likely due to lack of forward guidance or competitive concerns.

What is Linzess and what were its Q1 sales?

Linzess is a drug for irritable bowel syndrome with constipation. Its sales grew 15% year-over-year.

Ironwood Q1 Earnings Beat Estimates, Stock Slides Despite Strong Linzess Sales

Ironwood Pharmaceuticals (IRWD) reported Q1 earnings that beat analyst estimates, driven by strong Linzess sales. Revenue reached $123.4 million and EPS $0.12, but the stock declined in after-hours trading.

Ironwood Pharmaceuticals (IRWD) reported first-quarter 2026 results that surpassed analyst expectations for both revenue and earnings, fueled by robust demand for its key drug Linzess. Despite the positive results, the stock declined in post-market trading.

Key Financial Results

Metric	Q1 2026	Estimate	Difference
Revenue	$123.4M	$120M	+2.8%
EPS	$0.12	$0.10	+$0.02
Net Income	$18.5M	-	-

Highlights from the Release

Linzess sales grew 15% year-over-year, driven by new patient starts and improved adherence.
Operating revenue increased 12%.
Operating expenses decreased 3% due to cost-cutting measures.

Guidance

Ironwood did not provide formal guidance for the second quarter, but management indicated expectations for continued Linzess growth, with a focus on international expansion.

Stock Impact

Despite the earnings beat, IRWD shares fell 2.5% in after-hours trading. The decline may reflect investor concerns over the lack of forward guidance or competitive pressures in the gastrointestinal drug market.

What This Means for Investors

Ironwood's results underscore the strength of its lead product Linzess, but the absence of guidance creates uncertainty. Investors should monitor competitive developments and updates on the pipeline.